Schizophrenia and type 2 diabetes mellitus

Psychiatrikē = Psychiatriki
V MamakouV Kontaxakis

Abstract

Schizophrenia is associated with increased risk for type 2 diabetes mellitus, resulting in elevated cardiovascular risk and limited life expectancy, translated into a weighted average of 14.5 years of potential life lost and an overall weighted average life expectancy of 64.7 years. The exact prevalence of type 2 diabetes among people with schizophrenia varies across studies and ranges 2-5fold higher than in the general population, whereas the aetiology is complex and multifactorial. Besides common diabetogenic factors, applied similarly in the general population, such as obesity, hyperlipidemia, smoking, hypertension, poor diet and limited physical activity, the co-occurrence of schizophrenia and diabetes is also attributed to unique conditions. Specifically, excessive sedentary lifestyle, social determinants, adverse effects of antipsychotic drugs and limited access to medical care are considered aggravating factors for diabetes onset and low quality of diabetes management. Schizophrenia itself is further proposed as causal factor for diabetes, given the observed higher prevalence of diabetes in young patients, newly diagnosed with schizophrenia and unexposed to antipsychotics. Furthermore, studies support genetic predisposit...Continue Reading

Citations

May 29, 2019·Current Opinion in Psychiatry·Thomas M Laursen
Oct 28, 2019·Pharmacogenetics and Genomics·Henrik Thyge Corfitsen, Antonio Drago
Feb 11, 2020·Journal of Psychiatric and Mental Health Nursing·Trudy BrownMatthew Beverley-Stone
May 27, 2020·Obesity Surgery·Maíra E BritoAmilton Dos Santos-Júnior
Aug 10, 2020·Current Cardiology Reports·Jesper SvaneJacob Tfelt-Hansen
Nov 23, 2020·Social Psychiatry and Psychiatric Epidemiology·Tasuku Okui
Sep 24, 2019·Neuroscience and Biobehavioral Reviews·Gerwyn MorrisMichael Berk
Nov 12, 2019·Schizophrenia Research·Steven M SilversteinDocia L Demmin
Nov 13, 2020·Scientific Reports·Inmaculada Guerrero Fernández de AlbaAlexandra Prados-Torres
Nov 20, 2020·Brain Circulation·Leandro Bueno Bergantin
May 13, 2021·Acta Pharmacologica Sinica·De-Juan LiChang-Hua Hu
Jun 25, 2021·Frontiers in Neuroscience·Kevin K K YuAlex Kwok-Kuen Cheung
Jul 29, 2021·Progress in Neuro-psychopharmacology & Biological Psychiatry·Brittany RichardsonPanayotis K Thanos

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.